Yi-zhou Jiang

发表

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

R. Levy, J. Friedberg, I. Flinn, 2017, The New England journal of medicine.

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, C. Jacobson, N. Bartlett, 2017, Blood.

Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children

Yi-zhou Jiang, Jing Zhang, G. Shen, 2018, Medicine.

6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2011 .

Intra-Arterial Chemotherapy as Primary Therapy for Retinoblastoma in Infants Less than 3 Months of Age: A Series of 10 Case-Studies

Yi-zhou Jiang, Zhenyin Liu, Jing Zhang, 2016, PloS one.

Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial

Junjie Li, Guangyu Liu, Z. Shao, 2022, Cancer Biology & Medicine.

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

R. Donehower, Yi-zhou Jiang, K. Oliner, 2014, The Lancet. Oncology.

Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.

R. Donehower, Yi-zhou Jiang, S. Doshi, 2012 .

Outcome of intra‐arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study

Yi-zhou Jiang, Zhenyin Liu, Jing Zhang, 2017, Acta ophthalmologica.

Wedelolactone induces apoptosis and pyroptosis in retinoblastoma through promoting ROS generation.

Yi-zhou Jiang, Zhenyin Liu, Hua Jiang, 2022, International immunopharmacology.

Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival

Yi-zhou Jiang, G. Shen, Jing Zhang, 2015, Tumor Biology.

776 ITIL-306–201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

A. Ghobadi, Yi-zhou Jiang, S. Tykodi, 2022, Regular and Young Investigator Award Abstracts.

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

Yoon-Koo Kang, K. Muro, R. Jain, 2015 .

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

N. Bartlett, J. Rossi, S. Neelapu, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

Comparison between absolute ethanol and bleomycin for the treatment of venous malformation in children

Yi-zhou Jiang, Jing Zhang, Shao-yi Zhou, 2013, Experimental and therapeutic medicine.

Interventional embolization therapy of puerile congenital deep femoral arteriovenous fistula

Yi-zhou Jiang, Jing Zhang, Shao-yi Zhou, 2012, Experimental and therapeutic medicine.

A Randomized, Placebo‐Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum‐Based Chemotherapy as First‐Line Treatment for Extensive‐Stage Small‐Cell Lung Cancer

K. Nackaerts, R. Ramlau, L. Paz-Ares, 2017, Clinical lung cancer.

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

D. Miklos, C. Jacobson, N. Bartlett, 2020, Blood.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

D. Miklos, E. Jacobsen, C. Jacobson, 2018 .

Comparative study of sclerotherapy of venous malformation in children using absolute ethanol and pingyangmycin

Yi-zhou Jiang, Jing Zhang, Shao-yi Zhou, 2012 .

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2018, Biology of Blood and Marrow Transplantation.

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, E. Jacobsen, N. Bartlett, 2017 .

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).

D. Miklos, J. Rossi, C. Jacobson, 2017 .

Application of iron/barium ferrite/carbon-coated iron nanocrystal composites in transcatheter arterial chemoembolization of hepatocellular carcinoma.

Haiyan Zhang, Yunfei Deng, Yi-zhou Jiang, 2021, Journal of colloid and interface science.

Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2012 .

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

A. LaCasce, C. Jacobson, N. Bartlett, 2016 .

RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

D. Cunningham, N. Tebbutt, Yi-zhou Jiang, 2013 .

Latest evidence of microwave ablation for papillary thyroid microcarcinoma compared with surgery: A systematic review and meta-analysis

Yi-zhou Jiang, Yi-zhong Feng, Jie Feng, 2023, Frontiers in Oncology.

Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

M. Kersten, V. Plaks, Yi-zhou Jiang, 2019, Journal of Clinical Oncology.

O-0011 Evaluation of Met-Pathway Biomarkers in a Phase 2 Study of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine in Gastric/Esophagogastric Junction Cancer

R. Donehower, Yi-zhou Jiang, K. Oliner, 2012 .

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

S. Rosenberg, M. Roberts, A. Mardiros, 2015 .

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

M. Sabatino, J. Rossi, M. Bishop, 2017 .

Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China

Yi-zhou Jiang, J. Hua, Shen Gang, 2018, Journal of cancer research and therapeutics.

ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)

M. Kersten, G. Schiller, W. Wierda, 2016 .

Abstract LB150: Clinical Feasibility and Treatment Outcomes with Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients with Advanced Cutaneous Melanoma

P. Lorigan, F. Thistlethwaite, M. Pillai, 2021, Immunology.

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population

Yi-zhou Jiang, J. Ran, Ruihan Wu, 2023, BMC Gastroenterology.

Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)

J. Friedberg, D. Miklos, J. Rossi, 2017 .

Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial

D. Miklos, J. Rossi, E. Jacobsen, 2018 .

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

D. Miklos, C. Jacobson, N. Bartlett, 2017 .